Steady progress against HER2-positive breast ca... [N Engl J Med. 2011] - PubMed

loading

From the molecule to the clinic--inhibiting HER2 to treat breast cancer. [N Engl J Med. 2001]
From the molecule to the clinic--inhibiting HER2 to treat breast cancer.
Eisenhauer EA. N Engl J Med. 2001 Mar 15; 344(11):841-2.
ECOG E1100: a phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2). [Clin Adv Hematol Oncol. 2003]
ECOG E1100: a phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2).
[No authors listed]Clin Adv Hematol Oncol. 2003 Apr; 1(4):237.
HER2 and response to paclitaxel in node-positive breast cancer. [N Engl J Med. 2008]
HER2 and response to paclitaxel in node-positive breast cancer.
Roukos DH. N Engl J Med. 2008 Jan 10; 358(2):197; author reply 198.
Review [Her2 positive breast cancer: practices]. [Bull Cancer. 2011]
Review [Her2 positive breast cancer: practices].
Campone M, Berton-Rigaud D, Bourbouloux E, Sophie S, Zanetti A, Frenel JS. Bull Cancer. 2011 Feb; 98(2):154-63.
Review [Breast cancer]. [Nihon Rinsho. 2002]
Review [Breast cancer].
Tokuda Y, Saito Y, Suzuki Y, Ohta M, Tajima T. Nihon Rinsho. 2002 Mar; 60(3):563-9.

Design of clinical trials for biomarker research in oncology. [Clin Investig (Lond). 2011]
Design of clinical trials for biomarker research in oncology.
Mandrekar SJ, Sargent DJ. Clin Investig (Lond). 2011 Dec; 1(12):1629-1636.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Steady progress against HER2-positive breast cancer.
Steady progress against HER2-positive breast cancer.
N Engl J Med. 2011 Oct 6 ;365(14):1336-8. doi: 10.1056/NEJMe1101326.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed